{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:26:29Z","timestamp":1790724389721,"version":"4.1.0"},"reference-count":37,"publisher":"Termedia Sp. z.o.o.","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reumatologia"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Biological treatments are indicated in familial Mediterranean fever (FMF) patients with colchicine resistance or intolerance. Interleukin-1 (IL-1) inhibitors may not yield sufficient efficacy and safety. Interleukin-6 inhibitors (tocilizumab \u2013 TCZ) have been suggested to be potentially beneficial. This systematic literature review aimed to evaluate the\u00a0existing data on the\u00a0efficacy and safety of\u00a0IL-6 inhibitors in the\u00a0treatment of\u00a0FMF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and Methods<\/jats:title>\n                    <jats:p>A\u00a0systematic literature review was conducted using PubMed, Embase, Scopus, Web of\u00a0Science, and the\u00a0Cochrane Library to identify literature published until February 2024 on \u201cTocilizumab\u201d OR \u201cInterleukin-6 inhibitor\u201d AND \u201cFamilial Mediterranean Fever\u201d. This study was conducted according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A\u00a0total of\u00a011 studies were included, corresponding to 68 patients: 6 studies were case reports, 3 were case series, and 2 were randomized control trials. Tocilizumab was indicated mainly for amyloid A\u00a0(AA) amyloidosis and resistance\/intolerance to other drugs. Tocilizumab showed efficacy in controlling FMF attacks and disease symptoms including fever, abdominal pain, arthritis and arthralgia. Inflammatory markers including C-reactive protein and serum amyloid A\u00a0protein decreased. A\u00a0decrease in proteinuria levels was reported in 20 patients. Adverse events were recorded in one-third of\u00a0patients and led to TCZ discontinuation in 5 patients. No deaths associated with anti-IL-6 treatment were documented within a\u00a0median follow-up period of\u00a013 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although the\u00a0duration of\u00a0follow-up of\u00a0TCZ was short, we concluded that TCZ might present an acceptable profile regarding efficacy and safety in adult FMF patients. Our data suggest that TCZ could be a\u00a0good treatment option after IL-1 inhibitors and warrants further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5114\/reum\/199741","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T08:48:01Z","timestamp":1762850881000},"page":"337-347","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and safety of anti-interleukin-6 treatment in familial Mediterranean fever: a systematic literature review"],"prefix":"10.5114","volume":"63","author":[{"given":"Saidane","family":"Olfa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3820-0393","authenticated-orcid":true,"given":"Selma","family":"Bouden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameni","family":"Jerbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Rouached","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawdha","family":"Tekaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aicha","family":"Ben Tekaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Abdelmoula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3061","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"ref-1468224","unstructured":"Ben-Chetrit E, Yazici H. Familial Mediterranean fever: different faces around the world. Clin Exp Rheumatol 2019; 37 Suppl 6: 18\u201322."},{"key":"ref-1468225","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead514"},{"key":"ref-1468226","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-134932"},{"key":"ref-1468227","doi-asserted-by":"publisher","DOI":"10.3906\/sag-2008-11"},{"key":"ref-1468228","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa205"},{"key":"ref-1468229","doi-asserted-by":"publisher","DOI":"10.1186\/s42358-020-0117-1"},{"key":"ref-1468230","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.888392"},{"key":"ref-1468231","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010893.pub4"},{"key":"ref-1468232","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S102954"},{"key":"ref-1468233","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S206204"},{"key":"ref-1468234","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2018.1457469"},{"key":"ref-1468235","doi-asserted-by":"publisher","DOI":"10.1186\/s40348-016-0058-2"},{"key":"ref-1468236","doi-asserted-by":"crossref","unstructured":"Okuda Y. AA amyloidosis \u2013 benefits and prospects of IL-6 inhibitors. Mod Rheumatol 2019; 29: 268\u2013274, DOI: 10.1080\/ 14397595.2018.1515145.","DOI":"10.1080\/14397595.2018.1515145"},{"key":"ref-1468237","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05234-w"},{"key":"ref-1468238","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(23)00265-5"},{"key":"ref-1468239","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.284564"},{"key":"ref-1468240","doi-asserted-by":"publisher","DOI":"10.1097\/BPB.0000000000001104"},{"key":"ref-1468241","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003583"},{"key":"ref-1468242","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"ref-1468243","unstructured":"Wells GA, Shea B, O\u2019Connell D, et al. The Newcastle Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http:\/\/www.ohri.ca\/pro grams\/clinical_epidemiology\/oxford.asp, (n.d.)."},{"key":"ref-1468244","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.2277-18"},{"key":"ref-1468245","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2019.1709258"},{"key":"ref-1468246","unstructured":"Fujikawa K, Migita K, Tsukada T, et al. Interleukin-6 targeting therapy in familial Mediterranean fever. Clin Exp Rheumatol 2013; 31 (3 Suppl 77): 150\u2013151."},{"key":"ref-1468247","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2014.908810"},{"key":"ref-1468248","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11185360"},{"key":"ref-1468249","doi-asserted-by":"publisher","DOI":"10.1080\/24725625.2020.1739193"},{"key":"ref-1468250","unstructured":"Koga T, Sato S, Hagimori N, et al. A randomised, double-blind, placebo-controlled phase III trial on the efficacy and safety of tocilizumab in patients with familial Mediterranean fever. Clin Exp Rheumatol 2022; 40: 1535\u20131542, DOI: 10.55563\/ clinexprheumatol\/fgx9vv."},{"key":"ref-1468251","unstructured":"Serelis SFN, Christaki S. Remission of nephrotic syndrome due to AA-amyloidosis, complicating familiar Mediterranean fever, with tocilizumab. Clin Exp Rheumatol 2015; 33 (6 Suppl 94): S169."},{"key":"ref-1468252","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0642-0"},{"key":"ref-1468253","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.12776"},{"key":"ref-1468254","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu474"},{"key":"ref-1468255","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu"},{"key":"ref-1468256","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM-197410312911803"},{"key":"ref-1468257","unstructured":"Erden A, Batu EB, Sar\u0131 A, et al. Which definition should be used to determine colchicine resistance among patients with familial Mediterranean fever? Clin Exp Nephrol 2018; 36 (6 Suppl 115): 97\u2013102."},{"key":"ref-1468258","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-014-2772-2"},{"key":"ref-1468259","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-004-0925-4"},{"key":"ref-1468260","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1212640"}],"container-title":["Rheumatology"],"original-title":[],"link":[{"URL":"https:\/\/reu.termedia.pl\/pdf-199741-132048","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/reu.termedia.pl\/pdf-199741-132048","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T08:49:20Z","timestamp":1762850960000},"score":1,"resource":{"primary":{"URL":"https:\/\/reu.termedia.pl\/Efficacy-and-safety-of-anti-interleukin-6-treatment-in-familial-Mediterranean-fever,199741,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"alternative-id":["199741"],"URL":"https:\/\/doi.org\/10.5114\/reum\/199741","relation":{},"ISSN":["0034-6233","2084-9834"],"issn-type":[{"value":"0034-6233","type":"print"},{"value":"2084-9834","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]}}}